ResearcherAffiliated Hospital of Guizhou Medical UniversityNo recent work listed

Jie Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3432-8085; OpenAlex author ID A5100440076. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 2

KIF15 is essential for USP10-mediated PGK1 deubiquitination during the glycolysis of pancreatic cancer. Co-author DOI 10.1038/s41419-023-05679-2 ↗
KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. Co-author DOI 10.1038/bjc.2017.165 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jianxin Jiang · 2 shared papers, 2017–2023 · strength 0.32
- Paper KIF15 is essential for USP10-mediated PGK1 deubiquitination during the glycolysis of pancreatic cancer. DOI 10.1038/s41419-023-05679-2 ↗
- Paper KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. DOI 10.1038/bjc.2017.165 ↗
Jichuan Xu · 1 shared paper, 2023 · strength 0.22
- Paper KIF15 is essential for USP10-mediated PGK1 deubiquitination during the glycolysis of pancreatic cancer. DOI 10.1038/s41419-023-05679-2 ↗
Gang Quan · 1 shared paper, 2023 · strength 0.22
- Paper KIF15 is essential for USP10-mediated PGK1 deubiquitination during the glycolysis of pancreatic cancer. DOI 10.1038/s41419-023-05679-2 ↗
Xinyuan Liu · 1 shared paper, 2023 · strength 0.22
- Paper KIF15 is essential for USP10-mediated PGK1 deubiquitination during the glycolysis of pancreatic cancer. DOI 10.1038/s41419-023-05679-2 ↗
Xingjun Guo · 1 shared paper, 2017 · strength 0.10
- Paper KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. DOI 10.1038/bjc.2017.165 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.